SNG.L - Synairgen plc

LSE - LSE Delayed Price. Currency in GBp

Synairgen plc

Mailpoint 810
Level F, South Block
Southampton SO16 6YD
United Kingdom
44 23 8051 2800

Full Time Employees12

Key Executives

Mr. Richard MarsdenChief Exec. Officer, MD & Exec. DirectorN/AN/A50
Mr. John WardFin. Director, Company Sec. & Exec. Director156k220.5k56
Dr. Phillip David MonkChairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director143k293.15k49
Prof. Donna DaviesCo-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Prof. Ratko DjukanovicCo-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-??), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-?? that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in preclinical development for the treatment of idiopathic pulmonary fibrosis (IPF). Synairgen plc has research collaboration with Pharmaxis Ltd. to develop a LOXL2 inhibitor to the lysyl oxidase type 2 enzyme to treat IPF, a lung disease. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Corporate Governance

Synairgen plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.